Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

Shiyun Kim,1 Hugo Solari,2 Peter J Weiden,2 Jeffrey R Bishop11Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 2Department of Psychiatry, University of Illinois at Chicago College of Medicine, Chicago, IL, USAPurpose: To review the use of paliperidone palmitate...

Full description

Bibliographic Details
Main Authors:	Kim S, Solari H, Weiden PJ, Bishop JR
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-07-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/paliperidone-palmitate-injection-for-the-acute-and-maintenance-treatme-a10390

Similar Items

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
by: Mahlich J, et al.
Published: (2015-05-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
by: Takada R, et al.
Published: (2018-10-01)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01)

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report
by: Hassan Mirza, et al.
Published: (2018-09-01)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
by: Sliwa JK, et al.
Published: (2012-08-01)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
by: Zhang F, et al.
Published: (2015-03-01)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
by: Kadir Demirci, et al.
Published: (2015-01-01)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-02-01)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-01-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
by: Such P, et al.
Published: (2021-06-01)

Paliperidone palmitate-induced sialorrhoea
by: Cengiz Cengisiz, et al.
Published: (2016-03-01)

Accidental Overdose of Paliperidone Palmitate
by: Chiedozie Ojimba, et al.
Published: (2019-01-01)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
by: Brasso C, et al.
Published: (2017-11-01)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
by: Gattaz WF, et al.
Published: (2020-09-01)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
by: Sam Debaveye, et al.
Published: (2019-06-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Anderson, M., et al.
Published: (2021)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
by: Katy Mason, et al.
Published: (2021-07-01)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019-03-01)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
by: Juan J. Fernández-Miranda, et al.
Published: (2021-04-01)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs L, et al.
Published: (2013-03-01)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li HF, et al.
Published: (2015-12-01)

Clinical Study of Paliperidone Palmitate Long-Acting Injection Combined With Electroacupuncture in the Treatment of Methamphetamine Addicts
by: Yu Chen, et al.
Published: (2021-06-01)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
by: Lopez A, et al.
Published: (2019-02-01)

Paliperidone palmitate induced black hairy tongue
by: Bilge Burcak Annagur
Published: (2016-12-01)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
by: Enver Demirel Yılmaz, et al.
Published: (2014-01-01)

Quality of life of patients suffering from schizophrenia and treated with long-acting risperidone and paliperidone-palmitate
by: Mihajlović Filip, et al.
Published: (2018-01-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
by: Amber N. Edinoff, et al.
Published: (2021-09-01)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
by: O'Donnell A, et al.
Published: (2021-01-01)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
by: Rita deAzevedo Avelar, et al.
Published: (2020-12-01)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
by: Srihari Gopal, et al.
Published: (2017-07-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
by: Ma Yi-Wen, et al.
Published: (2011-04-01)

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia
by: Maria Paz Garcia-Portilla, et al.
Published: (2020-05-01)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
by: Takahashi N, et al.
Published: (2013-12-01)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
by: Si TM, et al.
Published: (2015-06-01)